289 related articles for article (PubMed ID: 12552250)
1. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
2. The Epstein-Barr virus BRLF1 gene product transactivates the murine and human c-myc promoters.
Gutsch DE; Marcu KB; Kenney SC
Cell Mol Biol (Noisy-le-grand); 1994 Sep; 40(6):747-60. PubMed ID: 7812182
[TBL] [Abstract][Full Text] [Related]
3. The LCR of EBV makes Burkitt's lymphoma endemic.
Niller HH; Salamon D; Banati F; Schwarzmann F; Wolf H; Minarovits J
Trends Microbiol; 2004 Nov; 12(11):495-9. PubMed ID: 15488390
[TBL] [Abstract][Full Text] [Related]
4. [Epstein-Barr virus and Burkitt's lymphoma].
Joab I
Med Trop (Mars); 1999; 59(4 Pt 2):499-502. PubMed ID: 10901854
[TBL] [Abstract][Full Text] [Related]
5. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
6. Epstein-Barr virus and Burkitt's lymphoma.
Magrath I; Jain V; Bhatia K
Semin Cancer Biol; 1992 Oct; 3(5):285-95. PubMed ID: 1335792
[TBL] [Abstract][Full Text] [Related]
7. Suppression of the malignant phenotype in somatic cell hybrids between Burkitt's lymphoma cells and Epstein-Barr virus-immortalized lymphoblastoid cells despite deregulated c-myc expression.
Wolf J; Pawlita M; Bullerdiek J; zur Hausen H
Cancer Res; 1990 May; 50(10):3095-100. PubMed ID: 2159373
[TBL] [Abstract][Full Text] [Related]
8. Frequent expansion of Epstein-Barr virus (EBV) infected cells in germinal centres of tonsils from an area with a high incidence of EBV-associated lymphoma.
Araujo I; Foss HD; Hummel M; Anagnostopoulos I; Barbosa HS; Bittencourt A; Stein H
J Pathol; 1999 Feb; 187(3):326-30. PubMed ID: 10398087
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells.
Jochner N; Eick D; Zimber-Strobl U; Pawlita M; Bornkamm GW; Kempkes B
EMBO J; 1996 Jan; 15(2):375-82. PubMed ID: 8617212
[TBL] [Abstract][Full Text] [Related]
10. Replacement of the Epstein-Barr virus plasmid with the EBER plasmid in Burkitt's lymphoma cells.
Maruo S; Nanbo A; Takada K
J Virol; 2001 Oct; 75(20):9977-82. PubMed ID: 11559830
[TBL] [Abstract][Full Text] [Related]
11. EBV-associated neoplasms: alternative pathogenetic pathways.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Schwarzmann F; Wolf H; Minarovits J
Med Hypotheses; 2004; 62(3):387-91. PubMed ID: 14975509
[TBL] [Abstract][Full Text] [Related]
12. Absence of a paused transcription complex from the c-myc P2 promoter of the translocation chromosome in Burkitt's lymphoma cells: implication for the c-myc P1/P2 promoter shift.
Strobl LJ; Kohlhuber F; Mautner J; Polack A; Eick D
Oncogene; 1993 Jun; 8(6):1437-47. PubMed ID: 8502472
[TBL] [Abstract][Full Text] [Related]
13. The intron enhancer of the immunoglobulin kappa gene activates c-myc but does not induce the Burkitt-specific promoter shift.
Polack A; Strobl L; Feederle R; Schweizer M; Koch E; Eick D; Wiegand H; Bornkamm GW
Oncogene; 1991 Nov; 6(11):2033-40. PubMed ID: 1945409
[TBL] [Abstract][Full Text] [Related]
14. Cell phenotype-dependent splicing reflecting differential promoter usage for EBNA transcripts in EBV-carrying cells.
Hu LF; Chen F; Altiok E; Winberg G; Klein G; Ernberg I
Gan To Kagaku Ryoho; 2000 May; 27 Suppl 2():248-60. PubMed ID: 10895161
[TBL] [Abstract][Full Text] [Related]
15. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
16. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
17. Epstein-Barr virus and its role in the pathogenesis of Burkitt's lymphoma: an unresolved issue.
Bornkamm GW
Semin Cancer Biol; 2009 Dec; 19(6):351-65. PubMed ID: 19619654
[TBL] [Abstract][Full Text] [Related]
18. Epstein-Barr virus-infected marmoset cells transfected with c-myc do not form lymphomas in mice with severe combined immunodeficiency.
Salimi B; O'Gorman MR; Variakojis D; Bendet M; Newman M; Poupko E; Katz BZ
Mol Genet Metab; 1998 Jul; 64(3):205-12. PubMed ID: 9719630
[TBL] [Abstract][Full Text] [Related]
19. Theophylline induced differentiation provides direct evidence for the deregulation of c-myc in Burkitt's lymphoma and suggests participation of immunoglobulin enhancer sequences.
Sandlund JT; Neckers LM; Schneller HE; Woodruff LS; Magrath IT
Cancer Res; 1993 Jan; 53(1):127-32. PubMed ID: 8416737
[TBL] [Abstract][Full Text] [Related]
20. Molecular mechanisms of transcriptional control of bcl-2 and c-myc in follicular and transformed lymphoma.
Arcinas M; Heckman CA; Mehew JW; Boxer LM
Cancer Res; 2001 Jul; 61(13):5202-6. PubMed ID: 11431360
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
